# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
On consummation of the merger, Rafael will issue Class B shares to Cyclo Therapeutics' shareholders, based on an exchange r...
Rafael Holdings (NYSE:RFL) reported quarterly earnings of $0.06 per share. This is a 125 percent increase over losses of $(0.24...
Continued strong enrollment of pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Diseas...
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.06) per share. This is a 78.57 percent increase over losses of $(0....
Rafael Holdings, Inc. (NYSE:RFL), today announced that its Board of Directors has authorized the repurchase of up to $5 million...